Grupo de investigación en neoplasias de línea mieloide

Área de Oncología

Análisis de los factores de riesgo de trombosis en mielofibrosis

Analizar pacientes diagnosticados de síndromes mielodisplásicos con deleción 20q y del(20q). Evaluar la incidencia, valor pronóstico e impacto en la respuesta a azacitidina

Analizar en pacientes diagnosticados de leucemias mieloides agudas y del(7q) la incidencia, valor pronóstico y potencial como diana terapéutica de deleciones cromosómicas del gen EZH2 y de alteraciones por mutaciones genéticas y otras mutaciones genéticas

Dra. Mar Tormo Díaz
Coordinadora
Dra. Mar Tormo Díaz
maria.mar.tormo@uv.es; tormo_mar@gva.es

INVESTIGADORES
R4 Senior

Mar Tormo Díaz    
Juan Carlos Hernández Boluda

R3 Consolidado

Eva Villamón Ribate

R2 Novel / Emergente

Iván Martín Castillo
Marisa Calabuig Muñoz

R1 Predoctoral

Alicia Borrero Abarca
Irene Pastor Galán

STAFF
Colaborador/a

Carlos Carretero Márquez
Montserrat Gómez Calafat

Enfermero/a

Mª Carmen Hurtado Fontelles

Técnico/a
Apoyo
Publicaciones
e14a2 transcript favors treatment-free remission in chronic myeloid leukemia when associated with longer treatment with tyrosine kinase inhibitors and sustained deep molecular response. Marce S, Mendez A, Xicoy B, Estrada N, Cabezon M, Sturla A, Garcia M, Angona A, Amat P, Serrat S, Scalzulli E, Morgades M, Senin A, Hernandez-Boluda J, Ferrer-Marin F, Anguita E, Cortes M, Plensa E, Breccia M, Garcia-Gutierrez V, Zamora L. Journal of Clinical Medicine. 2024 Jan 29;13(3):779. doi: 10.3390/jcm13030779. PMID: 38337473

Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology. Garrote M, López-Guerra M, García-Pagán JC, Arellano-Rodrigo E, Ferrer-Marín F, Hernández-Boluda JC, Bellosillo B, Nomdedeu M, Hernández-Gea V, Triguero A, Guijarro F, Álamo J, Baiges A, Turon F, Colomer D, Cervantes F, Alvarez-Larrán A. Annals of Hematology. 2024 Jan 24. doi: 10.1007/s00277-023-05610-x. PMID: 38263537.

Outcomes after intensive chemotherapy for secondary and myeloidrelated changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry. Martinez-Cuadron D, Megias-Vericat J, Gil C, Bernal T, Tormo M, Martinez-Sanchez P, Rodriguez-Medina C, Serrano J, Herrera P, Simon J, Sayas M, Bergua J, Lavilla-Rubira E, Amigo M, Benavente C, Lorenzo J, Perez-Encinas M, Vidriales M, Colorado M, De Rueda B, Garcia-Boyero R, Marini S, Garcia-Suarez J, Lopez-Pavia M, Gomez-Roncero M, Noriega V, Lopez A, Labrador J, Cabello A, Sossa C, Algarra L, Stevenazzi M, Solana-Altabella A, Boluda B, Montesinos P. Haematologica. 2024 Jan 1;109(1):115-128. doi: 10.3324/haematol.2022.282506. PMID: 37199127

Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes. Caballero J, Dávila J, López-Pavía M, Such E, Bernal T, Ramos F, Calabuig M, Sánchez J, Pomares H, Barba M, Abáigar M, González B, Merchán B, Sancho-Tello R, Callejas M, Muñoz-Novas C, Cerveró C, Sanz G, Rivas J, Campelo M. Therapeutic Advances in Hematology. 2024 Jan 4:15:20406207231218157. doi: 10.1177/20406207231218157. PMID: 38186638

Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. Jabbour E, Zugmaier G, Agrawal V, Martínez-Sánchez P, Roca J, Cassaday R, Böll B, Rijneveld A, Abdul-Hay M, Huguet F, Cluzeau T, Díaz M, Vucinic V, González-Campos J, Rambaldi A, Schwartz S, Berthon C, Hernández-Rivas J, Gordon P, Brüggemann M, Hamidi A, Chen Y, Wong H, Panwar B, Katlinskaya Y, Markovic A, Kantarjian H. American Journal of Hematology. 2024 Feb 5. doi: 10.1002/ajh.27227. PMID: 38317420

The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis. Hernández-Sánchez A, Villaverde-Ramiro A, Arellano-Rodrigo E, Garrote M, Martín I, Mosquera-Orgueira A, Gómez-Casares M, Ferrer-Marín F, Such E, Velez P, Ayala R, Angona A, de las Heras N, Magro E, Mata-Vázquez M, Fox M, de Villambrosía S, Ramírez M, García A, Garcia-Gutiérrez V, Caceres A, Duran M, Senín A, Raya J, González J, Cuevas B, Xicoy B, Pérez-Encinas M, Bellosillo B, Alvarez-Larrán A, Hernández-Rivas J, Hernández-Boluda J. American Journal of Hematology. 2024 Jan 30. doi: 10.1002/ajh.27203. PMID: 38291566

A novel ETV6: FGFR1 fusion gene in a myeloid/lymphoid neoplasm with FGFR1 rearrangement sensitive to specific FGFR1-2-3 inhibition. Jimenez-Vicente C, Garrote M, Lopez-Guerra M, Villamon E, Guijarro F, Perez-Valencia A, Martinez-Roca A, Balaguer O, Alvarez-Larran A, Hernandez-Boluda J, Rovira M, Colomer D, Diaz-Beya M, Rozman M, Esteve J. Leukemia & Lymphoma. 2023 Dec 20:1-5. doi: 10.1080/10428194.2023.2295788. PMID: 38117930

A simple prognostic system in myelofibrosis patients undergoing allogeneic stem cell transplant: a CIBMTR/EBMT analysis. Tamari R, McLornan D, Ahn K, Estrada-Merly N, Hernandez-Boluda J, Giralt S, Palmer J, Gale R, DeFilipp Z, Marks D, van der Poel M, Verdonck L, Battiwalla M, Diaz M, Gupta V, Ali H, Litzow M, Lazarus H, Gergis U, Bashey A, Liesveld J, Hashmi S, Pu J, Beitinjaneh A, Bredeson C, Rizzieri D, Savani B, Abid M, Ganguly S, Agrawal V, Ulrike V, Wirk B, Jain T, Cutler C, Aljurf M, Kindwall-Keller T, Kharfan-Dabaja M, Hildebrandt G, Pawarode A, Solh M, Yared J, Grunwald M, Nathan S, Nishihori T, Seo S, Scott B, Nakamura R, Oran B, Czerw T, Yakoub-Agha I, Saber W. Blood Advances. 2023 Aug 8;7(15):3993-4002. doi: 10.1182/bloodadvances.2023009886. PMID: 37134306

Adoptive immunotherapy via donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for myelofibrosis: a real-world, retrospective multicenter study. Rampotas A, Sockel K, Panitsas F, Theuser C, Bornhauser M, Hernani R, Hernandez-Boluda JC, Esquirol A, Avenoso D, Tsirigotis P, Robin M, Czerw T, Helbig G, Roddie C, Lambert J, McLornan DP. Transplantation and Cellular Therapy. 2023 Nov;29(11):687.e1-687.e7. doi: 10.1016/j.jtct.2023.08.020. PMID: 37633414

Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT. Hernandez-Boluda J, Eikema D, Koster L, Kroger N, Robin M, de Witte M, Finke J, Finazzi M, Broers A, Raida L, Schaap N, Chiusolo P, Verbeek M, Hazenberg C, Halaburda K, Kulagin A, Labussiere-Wallet H, Gedde-Dahl T, Rabitsch W, Raj K, Drozd-Sokolowska J, Battipaglia G, Polverelli N, Czerw T, Yakoub-Agha I, Mclornan D. Bone Marrow Transplantation. 2023 Dec;58(12):1357-1367. doi: 10.1038/s41409-023-02094-1. PMID: 37679647

Application of IPSET-thrombosis in 1366 patients prospectively followed from the Spanish Registry of essential thrombocythemia. Alvarez-Larrán A, Cuevas B, Velez P, Noya S, Caballero-Navarro G, Ferrer-Marín F, Carbonell S, Pérez-Encinas M, Gómez-Casares M, Pérez-López R, Magro E, Moretó A, Pastor-Galán I, Angona A, Mata-Vázquez M, Guerrero-Fernández L, Guerra J, Carreño-Tarragona G, Fox L, Murillo I, García-Gutiérrez V, Mora E, Stuckey R, Arellano-Rodrigo E, Hernández-Boluda J, Pereira A, MPN Spanish Grp GEMFIN. Hemasphere. 2023 Jul 18;7(8):e936. doi: 10.1097/HS9.0000000000000936. PMID: 37476303

Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: a proof-of-concept study. de la Asunción C, Giménez E, Hernández-Boluda J, Terol M, Albert E, López J, García-Gutiérrez V, Andreu R, Malo M, Fox M, Remigia M, Amat P, Solano C, Navarro D. Journal of Medical Virology. 2023 Jul;95(7):e28933. doi: 10.1002/jmv.28933. PMID: 37403897

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Kwon M, Iacoboni G, Reguera JL, Lopez Corral L, Hernani Morales R, Ortiz-Maldonado V, Guerreiro M, Caballero AC, Guerra Dominguez ML, Sanchez Pina JM, Mussetti A, Sancho JM, Bastos-Oreiro M, Catala E, Delgado J, Henriquez HL, Sanz J, Calbacho M, Bailen R, Carpio C, Ribera JM, Sureda A, Briones J, Hernandez-Boluda JC, Martinez Cebrian N, Diez Martin JL, Martin A, Barba P. Haematologica. 2023 Jan 1;108(1):110-121. doi: 10.3324/haematol.2022.280805. PMID: 35770532

CNL and aCML should be considered as a single entity based on molecular profiles and outcomes. Carreño-Tarragona G, Álvarez-Larrán A, Harrison C, Martínez-Ávila JC, Hernández-Boluda JC, Ferrer-Marín F, Radia DH, Mora E, Francis S, González-Martínez T, Goddard K, Pérez-Encinas M, Narayanan S, Raya JM, Singh V, Gutiérrez X, Toth P, Amat-Martínez P, Mcilwaine L, Alobaidi M, Mayani K, McGregor A, Stuckey R, Psaila B, Segura A, Alvares C, Davidson K, Osorio S, Cutting R, Sweeney CP, Rufián L, Moreno L, Cuenca I, Smith J, Morales ML, Gil-Manso R, Koutsavlis I, Wang L, Mead AJ, Rozman M, Martínez-López J, Ayala R, Cross NCP. Blood Advances. 2023 May 9;7(9):1672-1681. doi: 10.1182/bloodadvances.2022008204. PMID: 36375042

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group. Sargas C, Ayala R, Larrayoz M, Chillon M, Rodriguez-Arboli E, Bilbao C, Prados de la Torre E, Martinez-Cuadron D, Rodriguez-Veiga R, Boluda B, Gil C, Bernal T, Bergua J, Algarra L, Tormo M, Martinez-Sanchez P, Soria E, Serrano J, Alonso-Dominguez J, Garcia R, Amigo M, Herrera-Puente P, Sayas M, Lavilla-Rubira E, Martinez-Lopez J, Calasanz M, Garcia-Sanz R, Perez-Simon J, Gomez Casares M, Sanchez-Garcia J, Barragan E, Montesinos P. Blood Cancer Journal. 2023 May 12;13(1):77. doi: 10.1038/s41408-023-00835-5. PMID: 37173322

Current use of androgens in bone marrow failure disorders: a report from the Severe Aplastic Anemia Working Party of the European Society of Blood and Marrow Transplantation. Pagliuca S, Kulasekararaj A, Eikema D, Piepenbroek B, Iftikhar R, Satti T, Griffin M, Laurino M, Kupesiz A, Bertrand Y, Fattizzo B, Yakoub-Agha I, Aljurf M, Corti P, Massaccesi E, Lioure B, Calabuig M, Klammer M, Unal E, Wu D, Chevallier P, Forcade E, Snowden J, Ozdogu H, Risitano A, De Latour R. Haematologica. 2023 May 18. doi: 10.3324/haematol.2023.282935. PMID: 37199126

Cytogenetic assessment and risk stratification in myelofibrosis with optical genome mapping. Diaz-Gonzalez A, Mora E, Avetisyan G, Furio S, De la Puerta R, Gil J, Liquori A, Villamon E, Garcia-Hernandez C, Santiago M, Garcia-Ruiz C, Llop M, Ferrer-Lores B, Barragan E, Garcia-Palomares S, Mayordomo E, Luna I, Vicente A, Cordon L, Senent L, Alvarez-Larran A, Cervera J, De la Rubia J, Hernandez-Boluda J, Such E. Cancers. 2023 Jun 2;15(11):3039. doi: 10.3390/cancers15113039. PMID: 37297002

Cytomegalovirus DNAemia in hematological patients undergoing CD19-directed CAR-T cell therapy: should it be systematically monitored?. Solano de la Asuncion C, Hernani R, Albert E, Gomez M, Gimenez E, Benzaquen A, Gonzalez-Barbera E, Hernandez-Boluda J, Perez A, Pinana J, Chorao P, Guerreiro M, Montoro J, Sanz J, Solano C, Navarro D. Clinical Microbiology and Infection. 2023 Aug;29(8):1093-1095. doi: 10.1016/j.cmi.2023.05.010. PMID: 37182642

Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: a study on behalf of the Chronic Malignancies Working Party of the EBMT. Robin M, Gras L, Koster L, Gagelmann N, van Gorkom G, Ederr M, Itaelae-Remes M, Zuckerman T, Beguin Y, Schaap N, Drozd-Sokolowska J, Raj K, Hayden P, de Wreede L, Battipaglia G, Polverelli N, Czerw T, Boluda J, Krgöer N, Yakoub-agha I, McLornan D. British Journal of Haematology. 2023 Nov 28. doi: 10.1111/bjh.19214. PMID: 38014808

Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir. Gimenez E, Guerreiro M, Torres I, Aguilar C, Albert E, Hernandez-Boluda JC, Hernani R, Perez A, Amat P, Pinana JL, Montoro J, Solano C, Navarro D. Transplant Infectious Disease. 2023 Apr;25(2):e14021. doi: 10.1111/tid.14021. PMID: 36748748

Garcés-Carrasco AM, Santacatalina-Roig E, Carretero-Márquez C, Chover-Sierra E, Martínez-Sabater A, Balaguer-López E. Post-Transplant Complications in Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT)-A Comparative Analysis of Home Care versus Hospitalized Patients. Medicina (Kaunas). 2023 Dec 26;60(1):44. doi: 10.3390/medicina60010044. PMID: 38256305

Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials. Gonzalez-Gil C, Morgades M, Lopes T, Fuster-Tormo F, Garcia-Chica J, Zhao R, Montesinos P, Torrent A, Diaz-Beya M, Coll R, Hermosin L, Mercadal S, Gonzalez-Campos J, Zamora L, Artola T, Vall-Llovera F, Tormo M, Gil-Cortes C, Barba P, Novo A, Ribera J, Bernal T, De Ugarriza P, Queipo M, Martinez-Sanchez P, Gimenez A, Gonzalez-Martinez T, Cladera A, Cervera J, Fernandez-Martin R, Ardaiz M, Vidal M, Baena A, Lopez-Bigas N, Bigas A, Maciejewski J, Orfao A, Ribera J, Genesca E. Haematologica. 2023 Apr 1;108(4):969-980. doi: 10.3324/haematol.2022.281196. PMID: 36325893

Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors. Solano De la Asuncion C, Gimenez E, Hernandez-Boluda JC, Terol MJ, Albert E, Lopez-Jimenez J, Garcia-Gutierrez V, Andreu R, Garcia D, Fox ML, Remigia MJ, Amat P, Solano C, Navarro D. British Journal of Haematology. 2023 Mar;200(6):e58-e61. doi: 10.1111/bjh.18655. PMID: 36652997

Impact of cytomegalovirus immunodominant HLA-I donor-recipient matching on the incidence and features of virus DNAemia and virus-specific T-cell immune reconstitution in unmanipulated haploidentical hematopoietic stem cell transplantation. Huntley D, Gimenez E, Vazquez L, Pascual M, Amat P, Remigia M, Hernandez-Boluda J, Garcia M, Gago B, Torres I, de la Asuncion C, Hernani R, Perez A, Albert E, Pinana J, Solano C, Navarro D. Transplant Infectious Disease. 2023 Jun;25(3):e14065. doi: 10.1111/tid.14065. PMID: 37120821

Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia. Kayser S, Martinez-Cuadron D, Rodriguez-Veiga R, Hanel M, Tormo M, Schafer-Eckart K, Botella C, Stolzel F, Del Castillo TB, Keller U, Rodriguez-Medina C, Held G, Amigo ML, Schliemann C, Colorado M, Kaufmann M, Garcia MB, Krause SW, Gorner M, Jost E, Steffen B, Zukunft S, Platzbecker U, Ho AD, Baldus CD, Serve H, Muller-Tidow C, Thiede C, Bornhauser M, Montesinos P, Rollig C, Schlenk RF. Haematologica. 2023 Aug 1;108(8):2059-2066. doi: 10.3324/haematol.2022.282127. PMID: 36815361

Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion. Martin Castillo I, Villamon Ribate E, Calabuig Munoz M, Sanz Santillana G, Such Taboada E, Mora Castera E, Calasanz Abinzano MJ, Irigoyen Barranco A, Collado Nieto R, Vara Pampliega M, Blanco ML, Alvarez de Andres S, Perez de Oteyza J, Bernal del Castillo T, Granada Font I, Jerez Cayuela A, Diez-Campelo M, Abellan Sanchez R.; Solano Vercet C, Tormo Diaz M. Cancer Medicine. 2023 Aug;12(16):16788-16792. doi: 10.1002/cam4.6300. PMID: 37403747

Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group. Kröger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, Gupta V, Hamad N, Harrison C, Hernandez-Boluda JC, Koschmieder S, Jain T, Mascarenhas J, Mesa R, Popat UR, Passamonti F, Polverelli N, Rambaldi A, Robin M, Salit RB, Schroeder T, Scott BL, Tamari R, Tefferi A, Vannucchi AM, McLornan DP, Barosi G. Lancet. Haematology. 2023 Dec 4:S2352-3026(23)00305-8. doi: 10.1016/S2352-3026(23)00305-8. PMID: 38061384

Machine learning improves risk stratification in myelodysplastic neoplasms: an analysis of the Spanish Group of Myelodysplastic Syndromes. Mosquera Orgueira A, Perez Encinas M, Diaz Varela N, Mora E, Diaz-Beya M, Montoro M, Pomares H, Ramos F, Tormo M, Jerez A, Nomdedeu J, De Miguel Sanchez C, Leonor A, Carcel P, Cedena Romero M, Xicoy B, Rivero E, Del Orbe Barreto R, Diez-Campelo M, Benlloch L, Crucitti D, Valcarcel D. HemaSphere. 2023 Oct 11;7(10):e961. doi: 10.1097/HS9.0000000000000961. PMID: 37841754

Molecular landscape and validation of new genomic classification in 2668 Adult AML Patients: real life data from the PETHEMA Registry. Sargas C, Ayala R, Larrayoz MJ, Chillon MC, Carrillo-Cruz E, Bilbao-Sieyro C, Prados de la Torre E, Martinez-Cuadron D, Rodriguez-Veiga R, Boluda B, Gil C, Bernal T, Bergua JM, Algarra L, Tormo M, Martinez-Sanchez P, Soria E, Serrano J, Alonso-Dominguez JM, Garcia-Boyero R, Amigo ML, Herrera-Puente P, Sayas MJ, Lavilla-Rubira E, Martinez-Lopez J, Calasanz MJ, Garcia-Sanz R, Perez-Simon JA, Gomez-Casares MT, Sanchez-Garcia J, Barragan E, Montesinos P, on behalf of Pethema Group. Cancers. 2023 Jan 10;15(2):438. doi: 10.3390/cancers15020438. PMID: 36672386

One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients. Pinana JL, Vazquez L, Calabuig M, Lopez-Corral L, Martin-Martin G, Villalon L, Sanz-Linares G, Conesa-Garcia V, Sanchez-Salinas A, Gago B, Facal A, Risco-Galvez I, Olave MT, Espigado I, Lopez-Jimenez J, Hernandez-Rivas JA, Avendano-Pita A, Arroyo I, Ferrer E, Garcia-Cadenas I, Gonzalez-Santillana C, Roldan-Perez A, Ferrer B, Guerreiro M, Suarez-Lledo M, Camara A, Campos-Beltran D, Navarro D, Cedillo A, Sureda A, Solano C, Martino R. Blood Cancer Journal. 2023 Jan 5;13(1):8. doi: 10.1038/s41408-022-00778-3. PMID: 36599843

Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Orti G, Gras L, Zinger N, Finazzi M, Sockel K, Robin M, Forcade E, Avenoso D, Kroger N, Finke J, Radujkovic A, Hunault-Berger M, Schroyens W, Zuckerman T, Bourhis J, Chalandon Y, Bloor A, Schots R, de Wreede L, Drozd-Sokolowska J, Raj K, Polverelli N, Czerw T, Hernandez-Boluda J, McLornan D, Yakoub-Agha I. American Journal of Hematology. 2023 Apr;98(4):628-638. doi: 10.1002/ajh.26833. PMID: 36606718

Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain. Ortuzar A, Fox M, Vera J, Vizcaya A, Sanchez A, Calatayud I, Carbonell S, Alvarez-Larran A, Serna R, Buades J, Cervantes K, Hellin A, Dominguez A, Navarro G, Sansaloni A, Fernandez L, Linares C, Kabat M, Lopez R, Rodriguez A, Bilbao C, Rodriguez M, Diaz A, Duran M, Tomas M, Garcia-Gutierrez V, Mazo E, Hernandez-Boluda J, Segura A, Raya J, Elorza B, Osorio S. Annals of Hematology. 2023 Feb;102(2):447-456. doi: 10.1007/s00277-022-05044-x. PMID: 36422672

Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation. Coll C, de la Fe M, Garcia L, Vaz C, Fernando M, Almorox R, Garcia-Cadenas I, Munoz M, Ripa T, Al-Sibai J, Novoa S, Aguado B, Catarineu A, Lopez-Godino O, Bofarull R, Kwon M, Campos A, Barrigon D, Santasusana J. European Journal of Haematology. 2023 Jun;110(6):659-668. doi: 10.1111/ejh.13947. PMID: 36813736

SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination. Pinana J, Martino R, Vazquez L, Lopez-Corral L, Perez A, Chorao P, Avendano Pita A, Pascual M, Sanchez Salinas A, Sanz Linares G, Olave M, Arroyo I, Tormo M, Villalon L, Conesa Garcia V, Gago B, Terol M, Villalba M, Garcia Gutierrez V, Cabero A, Hernandez Rivas J, Ferrer E, Garcia Cadenas I, Teruel A, Navarro D, Cedillo A, Sureda A, Solano C. Bone Marrow Transplantation. 2023 Feb 28;1-14. doi: 10.1038/s41409-023-01946-0. PMID: 36854892

Should we move to a genomic classification of neutrophilic myeloid neoplasms?. Carreno-Tarragona G, Alvarez-Larran A, Hernandez-Boluda J, Ayala R, Cross N. Blood Advances. 2023 Nov 14;7(21):6705-6706. doi: 10.1182/bloodadvances.2023011103. PMID: 37672387

Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT. Polverelli N, Hernandez-Boluda J, Czerw T, Barbui T, D’Adda M, Deeg H, Ditschkowski M, Harrison C, Kroger N, Mesa R, Passamonti F, Palandri F, Pemmaraju N, Popat U, Rondelli D, Vannucchi A, Verstovsek S, Robin M, Colecchia A, Grazioli L, Damiani E, Russo D, Brady J, Patch D, Blamek S, Damaj G, Hayden P, McLornan D, Yakoub-Agha I. Lancet. Haematology. 2023 Jan;10(1):e59-e70. doi: 10.1016/S2352-3026(22)00330-1. PMID: 36493799

Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort. Onate G, Pratcorona M, Garrido A, Artigas-Baleri A, Bataller A, Tormo M, Arnan M, Vives S, Coll R, Salamero O, Vall-Llovera F, Sampol A, Garcia A, Cervera M, Avila S, Bargay J, Ortin X, Nomdedeu J, Esteve J, Sierra J. Blood Cancer Journal. 2023 May 5;13(1):69. doi: 10.1038/s41408-023-00839-1. PMID: 37147301

Torque Teno Virus plasma DNA load: a novel prognostic biomarker in CAR-T therapy. Benzaquén A, Giménez E, Iacoboni G, Guerreiro M, Hernani R, Albert E, Carpio C, Balaguer A, Pérez A, S de la Asunción C, Sánchez-Salinas MA, Chorão P, Piñana JL, Beas F, Montoro J, Hernández-Boluda JC, Facal A, Ferrer B, Villalba M, Amat P, Goméz MD, Campos D, Terol MJ, Sanz J, Barba P, Navarro D, Solano C. Bone Marrow Transplantation. 2023 Nov 2. doi: 10.1038/s41409-023-02114-0. PMID: 37919456

Toxicity of asciminib in real clinical practice: analysis of side effects and cross-toxicity with tyrosine kinase inhibitors. Perez-Lamas L, Luna A, Boque C, Xicoy B, Giraldo P, Perez Lopez R, Ruiz Nuno C, De Las Heras N, Mora Castera E, Lopez Marin J, Segura Diaz A, Gomez V, Velez Tenza P, Sierra Pacho M, Vera Goni JA, Moreno Vega M, Alvarez-Larran A, Cortes M, Perez Encinas M, Carrascosa Mastell P, Angona A, Rosell A, Lakhwani S, Colorado M, Ramila E, Cervero C, Cuevas B, Villalon Blanco L, de Paz R, Paz Coll A, Fernandez MJ, Felipe Casado L, Alonso-Dominguez JM, Anguita Arance MM, Salamanca Cuenca A, Jimenez-Velasco A, Prendes SO, Santaliestra M, Lis Chulvi MJ, Hernandez-Boluda JC, Garcia-Gutierrez V. Cancers. 2023 Feb 7;15(4):1045. doi: 10.3390/cancers15041045. PMID: 36831388

Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia. Simoes C, Villar S, Ariceta B, Garces J, Burgos L, Alignani D, Sarvide S, Martinez-Cuadron D, Bergua J, Vives S, Algarra L, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, Lopez-Lorenzo J, Vidriales M, Chillon C, Labrador J, Falantes J, Sayas M, Ayala R, Martinez-Lopez J, Pierola A, Calasanz M, Prosper F, San-Miguel J, Sanz M, Paiva B, Montesinos P. British Journal of Haematology. 2023 Jun;201(6):1239-1244. doi: 10.1111/bjh.18815. PMID: 37057357

5′-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics. Diaz-Santa J, Rodriguez-Romanos R, Coll R, Osca G, Pratcorona M, Gonzalez-Bartulos M, Garrido A, Angona A, Talarn C, Tormo M, Arnan M, Vives S, Salamero O, Tuset E, Lloveras N, Diez I, Zamora L, Bargay J, Sampol A, Cruz D, Vila J, Sitges M, Garcia A, Vall-Llovera F, Esteve J, Sierra J, Gallardo D. European Journal of Haematology. 2022 Dec;109(6):755-764. doi: 10.1111/ejh.13862. PMID: 36063368

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Ogasawara K, Cavenagh J, Silverman LR, Voso MT, Hellmann A, Tormo M, O’Connor T, Previtali A, Rose S, Garcia-Manero G. Blood Advances. 2022 Apr 12;6(7):2207-2218. doi: 10.1182/bloodadvances.2021005487. PMID: 34972214

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Hellmann A, Taussig DC, Tormo M, Voso MT, Cavenagh J, O’Connor T, Previtali A, Rose S, Silverman LR. Blood advances. 2022 Apr 12;6(7):2219-2229. doi: 10.1182/bloodadvances.2021006138. PMID: 34933333

Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: a series of 372 patients from the PETHEMA AML registry. Hernandez Boluda JC, Martinez Cuadron D, Pereira A, Rodriguez Veiga R, Boluda B, Gil C, Casal-Marini S, Serrano J, Martinez Lopez J, Bergua J, Algarra L, Bernal T, Lopez Lorenzo JL, Colorado M, Lopez A, Tormo M, Sayas MJ, Trigo F, Lopez Pavia M, Perez Simon JA, Lavilla Rubira E, Rodriguez Medina C, Rodriguez Gutierrez JI, Sanz Caballer MA, Montesinos P. Leukemia Research. 2022 Mar 6;115:106821. doi: 10.1016/j.leukres.2022.106821. PMID: 35286939

Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. Hernandez-Boluda J, Pereira A, Zinger N, Gras L, Martino R, Paneesha S, Finke J, Chinea A, Rambaldi A, Robin M, Saccardi R, Natale A, Snowden J, Tsirigotis P, Vallejo C, Wulf G, Xicoy B, Russo D, Maertens J, Daguindau E, Lenhoff S, Hayden P, Czerw T, McLornan D, Yakoub-Agha I. Bone Marrow Transplantation. 2022 Mar;57(3):416-422. doi: 10.1038/s41409-021-01553-x. PMID: 35066569

An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 Tyrosine Kinase Inhibitors. Garcia-Gutierrez V, Hernandez-Boluda JC. Expert Review of Hematology. 2022 Jun;15(6):477-484. doi: 10.1080/17474086.2022.2080049. PMID: 35583386

Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients. Pinana J, Rodriguez-Belenguer P, Caballero D, Martino R, Lopez-Corral L, Terol M, Vazquez L, Calabuig M, Sanz-Linares G, Marin-Jimenez F, Alonso C, Montoro J, Ferrer E, Facal A, Pascual M, Rodriguez-Fernandez A, Olave M, Cascales-Hernandez A, Gago B, Hernandez-Rivas J, Villalon L, Corona M, Roldan-Perez A, Ribes-Amoros J, Gonzalez-Santillana C, Garcia-Sanz R, Navarro D, Serrano-Lopez A, Cedillo A, Soria-Olivas E, Sureda A, Solano C. Annals of Hematology. 2022 Sep;101(9):2053-2067. doi: 10.1007/s00277-022-04906-8. PMID: 35780254

Azacitidine vs. Decitabine in unfit newly diagnosed acute myeloid leukemia patients: results from the PETHEMA Registry. Labrador J, Martinez-Cuadron D, de la Fuente A, Rodriguez-Veiga R, Serrano J, Tormo M, Rodriguez-Arboli E, Ramos F, Bernal T, Lopez-Pavia M, Trigo F, Martinez-Sanchez MP, Rodriguez-Gutierrez JI, Rodriguez-Medina C, Gil C, Garcia Belmonte D, Vives S, Foncillas MA, Perez-Encinas M, Novo A, Recio I, Rodriguez-Macias G, Bergua JM, Noriega V, Lavilla E, Roldan-Perez A, Sanz MA, Montesinos P, on Behalf of Pethema Group. Cancers. 2022 May 9;14(9):2342. doi: 10.3390/cancers14092342. PMID: 35565471

Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19. Piñana JL, Garcia-Sanz R, Martino R, Garcia-Roa M, Martin-Martin GA, Risco-Gálvez I, Tormo M, Martinez-Barranco P, Marcos-Corrales S, Calabuig M, Conesa V, Teruel A, Ruiz-Pérez S, Solano C, Navarro D, Cedillo Á, Sureda A. Blood Advances. 2022 Jan 8;6(3):848-853. doi: 10.1182/bloodadvances.2021006326. PMID: 34905620

Breakthrough infections in MPN-COVID vaccinated patients. Barbui T, Carobbio A, Ghirardi A, Iurlo A, De Stefano V, Sobas M, Rumi E, Elli E, Lunghi F, Kabat M, Cuevas B, Guglielmelli P, Bonifacio M, Marchetti M, Alvarez-Larran A, Fox L, Bellini M, Daffini R, Benevolo G, Carreno-Tarragona G, Patriarca A, Al-Ali H, Andrade-Campos M, Palandri F, Harrison C, Foncillas M, Osorio S, Koschmieder S, Mazo E, Kiladjian J, Calderon E, Heidel F, Cervantes K, Griesshammer M, Garcia-Gutierrez V, Sanchez A, Hernandez-Boluda J, Abadia E, Carli G, Serrano M, Kusec R, Cirici B, Guenova M, Elorza B, Angona A, Cichocka E, de Nalecz A, Cattaneo D, Bucelli C, Betti S, Borsani O, Cavalca F, Carbonell S, Curto-Garcia N, Benajiba L, Rambaldi A, Vannucchi A. Blood Cancer Journal. 2022 Nov 15;12(11):154. doi: 10.1038/s41408-022-00749-8. PMID: 36379921

Characteristics and outcomes of adult patients in the PETHEMA Registry with relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia. Martinez-Cuadron D, Serrano J, Mariz J, Gil C, Tormo M, Martinez-Sanchez P, Rodriguez-Arboli E, Garcia-Boyero R, Rodriguez-Medina C, Martinez-Chamorro C, Polo M, Bergua J, Aguiar E, Amigo M, Herrera P, Alonso-Dominguez J, Bernal T, Espadana A, Sayas M, Algarra L, Vidriales M, Vasconcelos G, Vives S, Perez-Encinas M, Lopez A, Noriega V, Garcia-Fortes M, Chillon M, Rodriguez-Gutierrez J, Calasanz M, Labrador J, Lopez J, Boluda B, Rodriguez-Veiga R, Martinez-Lopez J, Barragan E, Sanz M, Montesinos P. Cancers. 2022 Jun 6;14(11):2817. doi: 10.3390/cancers14112817. PMID: 35681796

Correction to: Low‑risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera. Triguero A, Pedraza A, Perez-Encinas M, Mata-Vazquez MI, Velez P, Fox L, Gomez-Calafat M, Garcia-Delgado R, Gasior M, Ferrer-Marin F, Garcia-Gutierrez V, Angona A, Gomez-Casares MT, Cuevas B, Martinez C, Perez R, Raya JM, Guerrero L, Murillo I, Bellosillo B, Hernandez-Boluda JC, Sanz C, Alvarez-Larran A. Annals of Hematology. 2022 Dec;101(12):2819-2820. doi: 10.1007/s00277-022-05005-4. PMID: 36264368

Correction: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. Hernandez-Boluda J, Pereira A, Zinger N, Gras L, Martino R, Nikolousis E, Finke J, Chinea A, Rambaldi A, Robin M, Saccardi R, Natale A, Snowden J, Tsirigotis P, Vallejo C, Wulf G, Xicoy B, Russo D, Maertens J, Daguindau E, Lenhoff S, Hayden P, Czerw T, McLornan D, Yakoub-Agha I. Bone Marrow Transplantation. 2022 Jun;57(6):1051. doi: 10.1038/s41409-022-01652-3. PMID: 35361897

Determinants of early triage for hospitalization in MPN patients with COVID-19. Barbui T, Carobbio A, Ghirardi A, Iurlo A, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, Bonifacio M, Alvarez-Larran A, Kiladjian JJ, Calderon E, Patriarca A, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Marin Sanchez A, Mazo E, Carli G, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Serrano M, Kusec R, Elorza B, Angona A, Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, de Nalecz AK, Cavalca F, Borsani O, Betti S, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi AM. American Journal of Hematology. 2022 Dec;97(12):E470-E473. doi: 10.1002/ajh.26732. PMID: 36111658

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Bataller A, Garrido A, Guijarro F, Onate G, Diaz-Beya M, Arnan M, Tormo M, Vives S, de Llano M, Coll R, Gallardo D, Vall-Llovera F, Escoda L, Garcia-Guinon A, Salamero O, Sampol A, Merchan B, Bargay J, Castano-Diez S, Esteban D, Oliver-Caldes A, Rivero A, Mozas P, Lopez-Guerra M, Pratcorona M, Zamora L, Costa D, Rozman M, Nomdedeu J, Colomer D, Brunet S, Sierra J, Esteve J. Blood advances. 2022 Feb 22;6(4):1193-1206. doi: 10.1182/bloodadvances.2021005585. PMID: 34911079

Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice. Montoro MJ, Pomares H, Coll R, Bernal Del Castillo T, Tormo M, Jimenez A, Brunet S, Casano J, Oiartzabal I, Diez-Campelo M, Ramos F, Romero R, Salido-Fierrez E, Pedro C, Bargay J, Munoz-Novas C, Lopez R, Rafel M, Valcarcel D. Leukemia & Lymphoma. 2022 Dec 28;1-12. doi: 10.1080/10428194.2022.2154604. PMID: 36577016

How I manage myeloproliferative neoplasm-unclassifiable: practical approaches for 2022 and beyond. McLornan D, Hargreaves R, Hernandez-Boluda J, Harrison C. British Journal of Haematology. 2022 May;197(4):407-416. doi: 10.1111/bjh.18087. PMID: 35191542

Impact of center-related characteristics and macroeconomic factors on the outcome of adult patients with acute lymphoblastic leukemia treated with pediatric-inspired protocols. Barba P, Morgades M, Montesinos P, Gonzalez-Campos J, Torrent A, Gil C, Bernal T, Tormo M, Mercadal S, Novoa S, Garcia-Cadenas I, Queipo de Llano MP, Cervera M, Coll R, Bermudez A, Amigo ML, Monsalvo S, Esteve J, Garcia-Boyero R, Novo A, Hernandez Rivas JM, Cladera A, Martinez-Sanchez P, Serrano J, Artola MT, Soria B, Abella E, Vall-Llovera F, Bergua J, Herrera P, Barrios D, Ribera JM. Hemasphere. 2022 Dec 23;7(1):e810. doi: 10.1097/HS9.0000000000000810. PMID: 36583094

Impact of donor-derived CD34+infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT. Czerw T, Iacobelli S, Malpassuti V, Koster L, Kroeger N, Robin M, Maertens J, Chevallier P, Watz E, Poire X, Snowden JA, Kuball J, Kinsella F, Blaise D, Remenyi P, Mear JB, Cammenga J, Rubio MT, Maury S, Daguindau E, Finnegan D, Hayden P, Hernandez-Boluda JC, McLornan D, Yakoub-Agha I. Bone Marrow Transplantation. 2022 Feb;57(2):261-270. doi: 10.1038/s41409-021-01540-2. PMID: 34853433

Impact of FLT3-ITD mutation status and its ratio in a cohort of 2901 patients undergoing upfront intensive chemotherapy: a PETHEMA Registry Study. Ayala R, Carreno-Tarragona G, Barragan E, Boluda B, Larrayoz M, Chillon M, Carrillo-Cruz E, Bilbao C, Sanchez-Garcia J, Bernal T, Martinez-Cuadron D, Gil C, Serrano J, Rodriguez-Medina C, Bergua J, Perez-Simon J, Calbacho M, Alonso-Dominguez J, Labrador J, Tormo M, Amigo M, Herrera-Puente P, Rapado I, Sargas C, Vazquez I, Calasanz M, Gomez-Casares T, Garcia-Sanz R, Sanz M, Martinez-Lopez J, Montesinos P. Cancers. 2022 Nov 24;14(23):5799. doi: 10.3390/cancers14235799. PMID: 36497281

Impact of individual comorbidities on survival of patients with myelofibrosis. García-Fortes M, Hernández-Boluda JC, Álvarez-Larrán A, Raya JM, Angona A, Estrada N, Fox L, Cuevas B, García-Hernández MC, Gómez-Casares MT, Ferrer-Marín F, Saavedra S, Cervantes F, García-Delgado R. Cancers. 2022 May 9;14(9):2331. doi: 10.3390/cancers14092331. PMID: 35565461

Impact of molecular profiling on the management of patients with myelofibrosis. Pastor-Galan I, Martin I, Ferrer B, Hernandez-Boluda J. Cancer Treatment Reviews. 2022 Jul 8;109:102435. doi: 10.1016/j.ctrv.2022.102435. PMID: 35839532

Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. Guijarro F, Bataller A, Diaz-Beya M, Garrido A, Coll-Ferra C, Vives S, Salamero O, Valcarcel D, Tormo M, Arnan M, Sampol A, Castano-Diez S, Martinez C, Suarez-Lledo M, Fernandez-Aviles F, Hernandez-Boluda J, Ribera J, Rovira M, Brunet S, Sierra J, Esteve J. Bone Marrow Transplantation. 2022 Aug;57(8):1304-1312. doi: 10.1038/s41409-022-01703-9. PMID: 35643942

Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera. Triguero A, Pedraza A, Perez-Encinas M, Mata-Vazquez MI, Velez P, Fox L, Gomez-Calafat M, Garcia-Delgado R, Gasior M, Ferrer-Marin F, Garcia-Gutierrez V, Angona A, Gomez-Casares MT, Cuevas B, Martinez C, Perez R, Raya JM, Guerrero L, Murillo I, Bellosillo B, Hernandez-Boluda JC, Sanz C, Alvarez-Larran A. Annals of Hematology. 2022 Oct;101(10):2231-2239. doi: 10.1007/s00277-022-04963-z. PMID: 36042023

Machine learning improves risk stratification in myelofibrosis: an analysis of the Spanish registry of myelofibrosis. Mosquera-Orgueira A, Perez-Encinas M, Hernandez-Sanchez A, Gonzalez-Martinez T, Arellano-Rodrigo E, Martinez-Elicegui J, Villaverde-Ramiro A, Raya JM, Ayala R, Ferrer-Marin F, Fox ML, Velez P, Mora E, Xicoy B, Mata-Vazquez MI, Garcia-Fortes M, Angona A, Cuevas B, Senin MA, Ramirez-Payer A, Ramirez MJ, Perez-Lopez R, Gonzalez de Villambrosia S, Martinez-Valverde C, Gomez-Casares MT, Garcia-Hernandez C, Gasior M, Bellosillo B, Steegmann JL, Alvarez-Larran A, Hernandez-Rivas JM, Hernandez-Boluda JC. Hemasphere. 2022 Dec 20;7(1):e818. doi: 10.1097/HS9.0000000000000818. PMID: 36570691

Multi-body-site colonization screening cultures for predicting multi-drug resistant Gram-negative and Gram-positive bacteremia in hematological patients. Torres I, Huntley D, Tormo M, Calabuig M, Hernandez-Boluda J, Terol M, Carretero C, de Michelena P, Perez A, Pinana J, Colomina J, Solano C, Navarro D. BMC Infectious Diseases. 2022 Feb 21;22(1):172. doi: 10.1186/s12879-022-07154-3. PMID: 35189833

Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: a retrospective study by the chronic malignancies working party of the EBMT. McLornan D, Gras L, Martin I, Sirait T, Schroeder T, Blau I, Kuball J, Byrne J, Collin M, Stadler M, Desmier D, Salmenniemi U, Jindra P, Mikhailova N, Lenhoff S, Rifon J, Robin M, Rovira M, Veelken H, Sadowska-Klasa A, Zecca M, Hayden P, Czerw T, Hernandez-Boluda J, Yakoub-Agha I. British Journal of Haematology. 2022 Jul;198(1):209-213. doi: 10.1111/bjh.18219. PMID: 35482558

Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: a combined CIBMTR/CMWP of EBMT analysis. Dholaria B, Radujkovic A, Estrada-Merly N, Sirait T, Kim S, Hernandez-Boluda J, Czerw T, Hayden P, Kansagra A, Ho V, Nishihori T, Shaughnessy P, Scott B, Nakamura R, Oran B, Kharfan-Dabaja M, Savani B, McLornan D, Yakoub-Agha I, Saber W. British Journal of Haematology. 2022 Aug;198(4):785-789. doi: 10.1111/bjh.18297. PMID: 35658101

Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin. Sangerman M, Moreno A, Quintana A, Garcia-Vidal C, Rubio M, Diaz M, Vendranas M, Macias G. Expert Review of Hematology. 2022 Mar;15(3):203-214. doi: 10.1080/17474086.2022.2054801. PMID: 35332831

Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis. Hernandez-Boluda JC, Pastor-Galan I, Arellano-Rodrigo E, Raya JM, Perez-Encinas M, Ayala R, Ferrer-Marin F, Velez P, Mora E, Fox ML, Hernandez-Rivas JM, Xicoy B, Mata-Vazquez MI, Garcia-Fortes M, Perez-Lopez R, Angona A, Cuevas B, Senin A, Ramirez MJ, Ramirez-Payer A, Gomez-Casares MT, Martinez-Valverde C, Magro E, Steegmann JL, Duran MA, Garcia-Hernandez C, Gasior M, de Villambrosia S, Alvarez-Larran A, Pereira A. British Journal of Haematology. 2022 Nov;199(4):529-538. doi: 10.1111/bjh.18440. PMID: 36089912

Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols. Ribera J, Granada I, Morgades M, Gonzalez T, Ciudad J, Such E, Calasanz M, Mercadal S, Coll R, Gonzalez-Campos J, Tormo M, Garcia-Cadenas I, Gil C, Cervera M, Barba P, Costa D, Ayala R, Bermudez A, Orfao A, Ribera J, Programa Tratamiento Hemopatias Ma, Spanish Soc Hematology, SEHH. British Journal of Haematology. 2022 Feb;196(3):670-675. doi: 10.1111/bjh.17844. PMID: 34549416

Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Onate G, Bataller A, Garrido A, Hoyos M, Arnan M, Vives S, Coll R, Tormo M, Sampol MA, Escoda L, Salamero O, Garcia A, Bargay J, Aljarilla A, Nomdedeu JF, Esteve J, Sierra J, Pratcorona M. Blood Advances. 2022 Feb 8;6(3):882-890. doi: 10.1182/bloodadvances.2020004136. PMID: 34516636

Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia. Luna A, Perez-Lamas L, Boque C, Giraldo P, Xicoy B, Ruiz Nuno C, Vega M, Alvarez-Larran A, Salamanca A, Garcia-Noblejas A, Vall-Llovera F, Villalon L, De Las Heras N, Ramila E, Perez-Encinas M, Cuevas B, Perez-Lopez R, Sanchez-Guijo F, Jimenez-Velasco A, Lakhwani S, Casado L, Rosell A, Escola A, Fernandez M, Garcia-Hernandez C, Cervero C, Mora E, Sagues M, Suarez-Varela S, Velez P, Carrascosa Mastell P, Bitaube R, Serrano L, Cortes M, Vera Goni J, Steegmann J, de Soria V, Alonso-Dominguez J, Araujo M, Coll A, Hernandez-Boluda J, Garcia-Gutierrez V. Annals of Hematology. 2022 Oct;101(10):2263-2270. doi: 10.1007/s00277-022-04932-6. PMID: 35997804

Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. Alvarez-Larran A, Garrote M, Ferrer-Marin F, Perez-Encinas M, Mata-Vazquez M, Bellosillo B, Arellano-Rodrigo E, Gomez M, Garcia R, Garcia-Gutierrez V, Gasior M, Cuevas B, Angona A, Gomez-Casares M, Martinez C, Magro E, Ayala R, del Orbe-Barreto R, Perez-Lopez R, Fox M, Raya J, Guerrero L, Garcia-Hernandez C, Caballero G, Murillo I, Xicoy B, Ramirez M, Carreno-Tarragona G, Hernandez-Boluda J, Pereira A. Cancer. 2022 Jul 1;128(13):2441-2448. doi: 10.1002/cncr.34195. PMID: 35417564

Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD. Vilorio-Marques L, Fernandez CC, Mora E, Gutierrez L; Rey Bua B, Jimenez Lorenzo MJ, Diaz Beya M, Vara Pampliega M, Molero A, Sanchez-Garcia J, Calabuig M, Cedena MT, Chen-Liang T, Diaz Santa JA, Padilla I, Hernandez F, Diez R, Asensi P, Xicoy B, Sanz G, Valcarcel D, Diez-Campelo M, Bernal T. Therapeutic Advances in Hematology. 2022 Sep 29;13:20406207221127547. doi: 10.1177/20406207221127547. PMID: 36199837

Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria. Triguero A, Xicoy B, Zamora L, Jimenez M, Garcia O, Calabuig M, Diaz-Beya M, Arzuaga J, Ramos F, Medina A, Bernal T, Talarn C, Coll R, Collado R, Chen T, Borras J, Brunet S, Marchante I, Marco V, Lopez-Cadenas F, Calbacho M, Simiele A, Cortes M, Cedena M, Pedreno M, Aguilar C, Pedro C, Fernandez M, Stoica C, Ribera J, Sanz G. Leukemia Research. 2022 May;116:106836. doi: 10.1016/j.leukres.2022.106836. PMID: 35405632

SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. Pinana JL, Lopez-Corral L, Martino R, Vazquez L, Perez A, Martin-Martin G, Gago B, Sanz-Linares G, Sanchez-Salinas A, Villalon L, Conesa-Garcia V, Olave MT, Corona M, Marcos-Corrales S, Tormo M, Hernandez-Rivas JA, Montoro J, Rodriguez-Fernandez A, Risco-Galvez I, Rodriguez-Belenguer P, Hernandez-Boluda JC, Garcia-Cadenas I, Ruiz-Garcia M, Munoz-Bellido JL, Solano C, Cedillo A, Sureda A, Navarro D. Journal of Hematology & Oncology. 2022 May 7;15(1):54. doi: 10.1186/s13045-022-01275-7. PMID: 35526045

Second versus first wave of COVID-19 in patients with MPN. Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Carioli G, Sobas M, Elli E, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Kabat M, Cuevas B, Fox M, Andrade-Campos M, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas M, Bonifacio M, Alvarez-Larran A, Kiladjian J, Calderon E, Patriarca A, Cervantes K, Griessammer M, Garcia-Gutierrez V, Sanchez A, Mazo E, Ruggeri M, Hernandez-Boluda J, Osorio S, Carreno-Tarragona G, Serrano M, Kusec R, Elorza B, Angona A, Cirici B, Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, de Nalecz A, Cavalca F, Borsani O, Betti S, Benajiba L, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi A. Leukemia. 2022 Mar;36(3):897-900. doi: 10.1038/s41375-022-01507-2. PMID: 35064223

Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. Pinana J, Vazquez L, Martino R, de la Camara R, Sureda A, Rodriguez-Veiga R, Garrido A, Sierra J, Ribera J, Torrent A, Mateos M, de la Rubia J, Tormo M, Diez-Campelo M, Garcia-Gutierrez V, Alvarez-Larran A, Sancho J, MartinGarcia-Sancho A, Yanez L, Simon J, Barba P, Abrisqueta P, Alvarez-Twose I, Bonanad S, Lecumberri R, Ruiz-Camps I, Navarro D, Hernandez-Rivas J, Cedillo A, Garcia-Sanz R, Bosch F. Leukemia & Lymphoma. 2022 Mar;63(3):538-550. doi: 10.1080/10428194.2021.1992619. PMID: 34668835

The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients. Villar S, Ariceta B, Agirre X, Urribarri A, Ayala R, Martinez-Cuadron D, Bergua J, Vives S, Algarra L, Tormo M, Martinez P, Serrano J, Simoes C, Herrera P, Calasanz M, Alfonso-Pierola A, Paiva B, Martinez-Lopez J, San Miguel J, Prosper F, Montesinos P. Frontiers in Oncology. 2022 Nov 24;12:1054458. doi: 10.3389/fonc.2022.1054458. PMID: 36505804

Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Martinez-Cuadron D, Megias-Vericat JE, Serrano J, Martinez-Sanchez P, Rodriguez-Arboli E, Gil C, Aguiar E, Bergua Burgues JM, Lopez-Lorenzo JL, Bernal T, Espadana A, Colorado M, Rodriguez-Medina C, Lopez-Pavia M, Tormo M, Algarra JL, Amigo ML, Sayas MJ, Labrador J, Rodriguez-Gutierrez JI, Benavente C, Costilla-Barriga L, Garcia-Boyero R, Lavilla E, Vives S, Herrera P, Garcia D, Herraez-Albendea MM, Esteves GV, Gomez-Roncero MI, Cabello A, Bautista G, Balerdi A, Mariz J, Boluda B, Sanz MA, Montesinos P. Blood Advances. 2022 Feb 22;6(4):1278-1295. doi: 10.1182/bloodadvances.2021005335. PMID: 34794172

Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience. Labrador J, Saiz-Rodriguez M, de Miguel D, de Laiglesia A, Rodriguez-Medina C, Vidriales M, Perez-Encinas M, Sanchez-Sanchez M, Cuello R, Roldan-Perez A, Vives S, Benzo-Callejo G, Colorado M, Garcia-Fortes M, Sayas M, Olivier C, Recio I, Conde-Royo D, Bienert-Garcia A, Vahi M, Munoz-Garcia C, Seri-Merino C, Tormo M, Vall-Llovera F, Foncillas M, Martinez-Cuadron D, Sanz M, Montesinos P. Cancers. 2022 Mar 29;14(7):1734. doi: 10.3390/cancers14071734. PMID: 35406512

A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia. Vives S, Martinez-Cuadron D, Bergua Burgues J, Algarra L, Tormo M, Martinez-Sanchez M, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Lopez-Lorenzo J, Gil C, Vidriales B, Falantes J, Serrano A, Labrador J, Sayas M, Foncillas M, Amador Barciela M, Olave M, Colorado M, Gascon A, Fernandez M, Simiele A, Perez-Encinas M, Rodriguez-Veiga R, Garcia O, Martinez-Lopez J, Barragan E, Paiva B, Sanz M, Montesinos P, PETHEMA Group. Cancer. 2021 Jun 15;127(12):2003-2014. doi: 10.1002/cncr.33403. PMID: 33626197

Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). Genesca E, Morgades M, Gonzalez-Gil C, Fuster-Tormo F, Haferlach C, Meggendorfer M, Montesinos P, Barba P, Gil C, Coll R, Moreno MJ, Martinez-Carballeira D, Garcia-Cadenas I, Vives S, Ribera J, Gonzalez-Campos J, Diaz-Beya M, Mercadal S, Artola MT, Cladera A, Tormo M, Bermudez A, Vall-Llovera F, Martinez-Sanchez P, Amigo ML, Monsalvo S, Novo A, Cervera M, Garcia-Guinon A, Ciudad J, Cervera J, Hernandez-Rivas JM, Granada I, Haferlach T, Orfao A, Sole F, Ribera JM. Leukemia Research. 2021 Jun 8;109:106612. doi: 10.1016/j.leukres.2021.106612. PMID: 34139642

Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. McLornan D, Boluda J, Czerw T, Cross N, Deeg H, Ditschkowski M, Moonim M, Polverelli N, Robin M, Aljurf M, Conneally E, Hayden P, Yakoub-Agha I. Leukemia. 2021 Sep;35(9):2445-2459. doi: 10.1038/s41375-021-01294-2. PMID: 34040148

Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: a study of the Chronic Malignancies Working Party of EBMT and the Spanish Myelofibrosis Registry. Hernandez-Boluda JC, Pereira A, Kroger N, Cornelissen JJ, Finke J, Beelen D, de Witte M, Wilson K, Platzbecker U, Sengeloev H, Blaise D, Einsele H, Sockel K, Kruger W, Lenhoff S, Salaroli A, Martin H, Garcia-Gutierrez V, Pavone V, Alvarez-Larran A, Raya JM, Zinger N, Gras L, Hayden P, Czerw T, McLornan D, Yakoub-Agha I. American Journal of Hematology. 2021 Oct 1;96(10):1186-1194. doi: 10.1002/ajh.26279. PMID: 34152630

An investigation of the potential association between gastrointestinal viral and bacterial infection and development of intestinal acute graft versus host disease following allogeneic hematopoietic stem cell transplantation. Bueno F, Albert E, Gimenez E, Pinana J, Perez A, Gomez M, Hernandez-Boluda J, Gonzalez-Barbera E, Montoro J, Buesa J, Guerreiro M, Balaguer-Rosello A, Hernani R, Sanz J, Solano C, Navarro D. Journal of Medical Virology. 2021 Aug;93(8):4773-4779. doi: 10.1002/jmv.26892. PMID: 33605457

Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroid-resistant acute and chronic graft-vs-host disease after allogenic hematopoietic stem cell transplant. Amat P, Lopez-Corral L, Goterris R, Perez A, Lopez O, Heras I, Arbona C, Viguria MC, Hernandez-Boluda JC, Martinez-Ruiz F, Martinez A, Solano C. Journal of Clinical Apheresis. 2021 Oct;36(5):697-710. doi: 10.1002/jca.21918. PMID: 34185332

CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review. Hernani R, Sancho A, Amat P, Hernandez-Boluda J, Perez A, Pinana J, Carretero C, Goterris R, Gomez M, Saus A, Ferrer B, Teruel A, Terol M, Solano C. Current Research in Translational Medicine. 2021 Jul 22;69(4):103304. doi: 10.1016/j.retram.2021.103304. PMID: 34303899

Chemotherapy or Allogeneic Transplantation in High-Risk Philadelphia Chromosome-Negative Adult Lymphoblastic Leukemia. Ribera J, Morgades M, Ciudad J, Montesinos P, Esteve J, Genesca E, Barba P, Ribera J, Garcia Cadenas I, Moreno M, Martinez-Carballeira D, Torrent A, Martinez-Sanchez P, Monsalvo S, Gil C, Tormo M, Artola M, Cervera M, Gonzalez-Campos J, Rodriguez-Medina C, Bermudez A, Novo A, Soria B, Coll R, Amigo M, Lopez A, Fernandez Martin R, Serrano J, Mercadal S, Cladera A, Gimenez-Conca A, Penarrubia M, Abella E, Vall-Llovera F, Hernandez-Rivas J, Garcia A, Bergua Burgues J, de Rueda B, Sanchez-Sanchez M, Serrano A, Calbacho M, Alonso Vence N, Mendez-Sanchez J, Garcia-Boyero R, Olivares M, Barrena S, Zamora L, Granada I, Lhermitte L, Feliu E, Orfao A. Blood. 2021 Apr 8;137(14):1879-1894. doi: 10.1182/blood.2020007311. PMID: 33150388

Correction: Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. McLornan D, Hernandez-Boluda J, Czerw T, Cross N, Deeg H, Ditschkowski M, Moonim M, Polverelli N, Robin M, Aljurf M, Conneally E, Hayden P, Yakoub-Agha I. Leukemia. 2021 Dec;35(12):3625. doi: 10.1038/s41375-021-01395-y. PMID: 34471230

Cytoreductive treatment in patients withCALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia. Alvarez-Larran A, Angona A, Andrade-Campos M, Soledad Noya M, Teresa Gomez-Casares M, Cuevas B, Caballero G, Garcia-Hernandez C, Garcia-Gutierrez V, Palomino A, Ferrer-Marin F, Isabel Mata-Vazquez M, Moreto A, Magro E, Murillo I, Alonso-Dominguez J, Maria Guerra J, Guerrero L, Maria Raya J, Perez-Encinas M, Carreno-Tarragona G, Fox L, Pastor Galan I, Bellosillo B, Hernandez Boluda J, MPN Spanish Grp Gemfin. British Journal of Haematology. 2021 Mar;192(6):988-996. doi: 10.1111/bjh.16988. PMID: 32745264

Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. Hernandez Boluda J, Pereira A, Kroeger N, Beelen D, Robin M, Bornhaeuser M, Angelucci E, Vitek A, Blau I, Niittyvuopio R, Finke J, Cornelissen J, Passweg J, Dreger P, Petersen E, Kanz L, Sanz J, Zuckerman T, Zinger N, Iacobelli S, Hayden P, Czerw T, McLornan D, Yakoub-Agha I. Leukemia. 2021 Jan;35(1):215-224. doi: 10.1038/s41375-020-0815-z. PMID: 32286544

Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival. Cabezon M, Malinverni R, Bargay J, Xicoy B, Marce S, Garrido A, Tormo M, Arenillas L, Coll R, Borras J, Jimenez M, Hoyos M, Valcarcel D, Escoda L, Vall-Llovera F, Garcia A, Font L, Ramila E, Buschbeck M, Zamora L, CETLAM Grp. Clinical Epigenetics. 2021 Jan 14;13(1):9. doi: 10.1186/s13148-021-01002-y. PMID: 33446256

Diversity and dynamic changes of Anelloviruses in plasma following Allogeneic Hematopoietic Stem Cell Transplantation. Gimenez Quiles E, Monzo Cataluña C, Albert Vicent E, Fuentes Trillo A, Seda García E, Pinana J, Hernandez Boluda J, Solano Vercet C, Chaves Martínez F, Navarro Ortega D. Journal of Medical Virology. 2021 Aug;93(8):5167-5172. doi: 10.1002/jmv.26661. PMID: 33174620

European wide survey on allogeneic haematopoietic cell transplantation practice for myelofibrosis on behalf of the EBMT chronic malignancies working party. McLornan D, Sirait T, Hernandez-Boluda J, Czerw T, Hayden P, Yakoub-Agha I. Current Research in Translational Medicine. 2021 Jan;69(1):103267. doi: 10.1016/j.retram.2020.08.003. PMID: 33069640

Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients. Boluda B, Martinez-Cuadron D, Algarra L, Cano I, Sayas M, Acuna-Cruz E, Blanco A, Marco-Ayala J, DeLapuerta R, Diaz-Gonzalez A, Tormo M, Rodriguez-Veiga R, Garcia R, Pinana J, Lopez-Pavia M, Barragan E, Amigo M, Sargas C, Lopez A, Solana-Altabella A, Gil C, Megias-Vericat J, Sanz M, Montesinos P. Leukemia & Lymphoma. 2021 Nov;62(11):2727-2736. doi: 10.1080/10428194.2021.1938031. PMID: 34121593

Evolving treatment patterns and outcomes in older patients (?60 years) with AML: changing everything to change nothing?. Martinez-Cuadron D, Serrano J, Gil C, Tormo M, Martinez-Sanchez P, Perez-Simon J, Garcia-Boyero R, Rodriguez-Medina C, Lopez-Pavia M, Benavente C, Bergua J, Lavilla-Rubira E, Amigo M, Herrera P, Alonso-Dominguez J, Bernal T, Colorado M, Sayas M, Algarra L, Vidriales M, Rodriguez-Macias G, Vives S, Perez-Encinas M, Lopez A, Noriega V, Garcia-Fortes M, Ramos F, Rodriguez-Gutierrez J, Costilla-Barriga L, Labrador J, Boluda B, Rodriguez-Veiga R, Martinez-Lopez J, Sanz M, Montesinos P. Leukemia. 2021 Jun;35(6):1571-1585. doi: 10.1038/s41375-020-01058-4. PMID: 33077867

Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Montoro J, Roldan E, Pinana J, Barba P, Chorao P, Quintero A, Hernani R, Orti G, Lorenzo J, Balaguer-Rosello A, Salamero O, Fox L, Solves P, Gomez I, Guerreiro M, Boluda J, Sanz G, Solano C, Sanz M, Valcarcel D, Sanz J. European Journal of Haematology. 2021 Jan;106(1):114-125. doi: 10.1111/ejh.13529. PMID: 33025625

Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea. Alvarez-Larran A, Diaz-Gonzalez A, Such E, Mora E, Andrade-Campos M, Garcia-Hernandez C, Gomez-Casares M, Garcia-Gutierrez V, Carreno-Tarragona G, Garrote M, Fernandez-Ibarrondo L, Cervera J, Bellosillo B, Cervantes F, Hernandez-Boluda J, MPN Spanish Group (GEMFIN). Leukemia. 2021 Feb;35(2):623-627. doi: 10.1038/s41375-020-0849-2. PMID: 32372025

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Barbui T, Vannucchi A, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Rossi G, Elli E, Andrade-Campos M, Kabat M, Kiladjian J, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox M, Foncillas M, Morcillo C, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes K, Serrano M, Carreno-Tarragona G, Sobas M, Lunghi F, Patriarca A, Elorza B, Angona A, Mazo E, Koschmieder S, Ruggeri M, Cuevas B, Hernandez-Boluda J, Abadia E, Cirici B, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, De Stefano V, Harrison C, Rambaldi A. Leukemia. 2021 Feb;35(2):485-493. doi: 10.1038/s41375-020-01107-y. PMID: 33414483

Impact of BCR-ABL1 transcript type on response, treatment-free remission rate and survival in chronic myeloid leukemia patients treated with imatinib. Marce S, Xicoy B, Garcia O, Cabezon M, Estrada N, Velez P, Boque C, Sagues M, Angona A, Teruel-Montoya R, Ferrer-Marin F, Amat P, Hernandez-Boluda J, Ibarra M, Anguita E, Cortes M, Fernandez-Ruiz A, Fontanals S, Zamora L, Grp Espanol Leucemia Mieloide Cron. Journal of Clinical Medicine. 2021 Jul 16;10(14):3146. doi: 10.3390/jcm10143146. PMID: 34300312

Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). Polverelli N, Mauff K, Kroger N, Robin M, Beelen D, Beauvais D, Chevallier P, Mohty M, Passweg J, Rubio M, Maertens J, Finke J, Bornhauser M, Vrhovac R, Helbig G, Mear J, Castagna L, Remenyi P, Angelucci E, Karakasis D, Rifon J, Sirait T, Russo D, de Wreede L, Czerw T, Hernandez-Boluda J, Hayden P, McLornan D, Yakoub-Agha I. American Journal of Hematology. 2021 Jan;96(1):69-79. doi: 10.1002/ajh.26020. PMID: 33064301

Long-term follow-up of recovered MPN patients with COVID-19. Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Rossi G, Harrison C, Alvarez-Larran A, Elli E, Kiladjian J, Kabat M, Sanchez A, Palandri F, Andrade-Campos M, Vannucchi A, Carreno-Tarragona G, Papadopoulos P, Cervantes K, Foncillas M, Fox M, Serrano M, Rumi E, Osorio S, Benevolo G, Patriarca A, Elorza B, Garcia-Gutierrez V, Mazo E, Lunghi F, Bonifacio M, De Stefano V, Hernandez-Boluda J, Abadia E, Angona A, Cirici B, Ruggeri M, Koschmieder S, Sobas M, Cuevas B, Cattaneo D, Daffini R, Bellini M, Curto-Garcia N, Garrote M, Cavalca F, Benajiba L, Bellosillo B, Guglielmelli P, Borsani O, Betti S, Salmoiraghi S, Rambaldi A. Blood Cancer Journal. 2021 Jun 16;11(6):115. doi: 10.1038/s41408-021-00509-0. PMID: 34135309

Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial. Simoes C, Paiva B, Martinez-Cuadron D, Bergua J, Vives S, Algarra L, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, Lopez J, Vidriales M, Labrador J, Falantes J, Sayas M, Ayala R, Martinez-Lopez J, Villar S, Calasanz M, Prosper F, San-Miguel J, Sanz M, Montesinos P. Blood Advances. 2021 Feb 9;5(3):760-770. doi: 10.1182/bloodadvances.2020003195. PMID: 33560390

Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations. Martin I, Villamon E, Abellan R, Calasanz M, Irigoyen A, Sanz G, Such E, Mora E, Gutierrez M, Collado R, Garcia-Serra R, Vara M, Blanco M, Oiartzabal I, Alvarez S, Bernal T, Granada I, Xicoy B, Jerez A, Calabuig M, Diez R, Gil A, Diez-Campelo M, Solano C, Tormo M, Spanish Grp Myelodysplastic Syn. British Journal of Haematology. 2021 Aug;194(4):708-717. doi: 10.1111/bjh.17675. PMID: 34296432

Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML Project. Sargas C, Ayala R, Chillon M, Larrayoz M, Carrillo-Cruz E, Bilbao C, Yebenes-Ramirez M, Llop M, Rapado I, Garcia-Sanz R, Vazquez I, Soria E, Florido-Ortega Y, Janusz K, Botella C, Serrano J, Martinez-Cuadron D, Bergua J, Amigo M, Martinez-Sanchez P, Tormo Diaz M, Bernal T, Herrera-Puente P, Garcia R, Algarra L, Sayas M, Costilla-Barriga L, Perez-Santolalla E, Marchante I, Lavilla-Rubira E, Noriega V, Alonso-Dominguez J, Sanz M, Sanchez-Garcia J, Gomez-Casares M, Perez-Simon J, Calasanz M, Gonzalez-Diaz M, Martinez-Lopez J, Barragan E, Montesinos P. Haematologica. 2021 Dec 1;106(12):3079-3089. doi: 10.3324/haematol.2020.263806. PMID: 33179471

Outcome of older (>= 70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study (vol 34, pg 2333, 2020). Kayser S, Rahme R, Martinez-Cuadron D, Ghiaur G, Thomas X, Sobas M, Guerci-Bresler A, Garrido A, Pigneux A, Gil C, Raffoux E, Tormo M, Vey N, de la Serna J, Salamero O, Lengfelder E, Levis MJ, Fenaux P, Sanz MA, Platzbecker U, Schlenk RF, Ades L, Montesinos P. Leukemia. 2021 Dec;35(12):3631. doi: 10.1038/s41375-021-01358-3. PMID: 34785795

Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials. Ribera J, Morgades M, Genesca E, Chapchap E, Montesinos P, Acuna-Cruz E, Gil C, Garcia-Cadenas I, Barba P, Gonzalez-Campos J, de Llano M, Torrent A, Ribera J, Granada I, Bernal T, Diaz-Beya M, Amigo M, Coll R, Tormo M, Vall-llovera F, Gomez-Centurion I, Sanchez-Sanchez M, Soria B, Cladera A, Artola M, Garcia-Guinon A, Gimenez-Conca A, Amador M, Martinez-Sanchez P, Algarra J, Vidal M, Alonso N, Maluquer C, Llorente L, Garcia-Boyero R, Ciudad J, Feliu E, Orfao A, PETHEMA Grp. Hematological Oncology. 2021 Oct;39(4):529-538. doi: 10.1002/hon.2910. PMID: 34405901

Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT. Nabergoj M, Mauff K, Robin M, Kroger N, Angelucci E, Poire X, Passweg J, Radujkovic A, Platzbecker U, Robinson S, Rambaldi A, Petersen S, Stolzel F, Stelljes M, Ciceri F, Mayer J, Ladetto M, de Wreede L, Koster L, Hayden P, Czerw T, Hernandez-Boluda J, McLornan D, Chalandon Y, Yakoub-Agha I. Bone Marrow Transplantation. 2021 Aug;56(8):1944-1952. doi: 10.1038/s41409-021-01271-4. PMID: 33824436

Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. Pleyer L, Leisch M, Kourakli A, Padron E, Maciejewski J, Xicoy Cirici B, Kaivers J, Ungerstedt J, Heibl S, Patiou P, Hunter A, Mora E, Geissler K, Dimou M, Jimenez Lorenzo M, Melchardt T, Egle A, Viniou A, Patel B, Arnan M, Valent P, Roubakis C, Bernal Del Castillo T, Galanopoulos A, Calabuig Munoz M, Bonadies N, Medina de Almeida A, Cermak J, Jerez A, Montoro M, Cortes A, Avendano Pita A, Lopez Andrade B, Hellstroem-Lindberg E, Germing U, Sekeres M, List A, Symeonidis A, Sanz G, Larcher-Senn J, Greil R. Lancet. Haematology. 2021 Feb;8(2):e135-e148. doi: 10.1016/S2352-3026(20)30374-4. PMID: 33513373

The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the PETHEMA-FLUGAZA phase 3 clinical trial. Ayala R, Rapado I, Onecha E, Martinez-Cuadron D, Carreno-Tarragona G, Bergua J, Vives S, Algarra J, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, Lorenzo J, Vidriales M, Labrador J, Falantes J, Sayas M, Paiva B, Barragan E, Prosper F, Sanz M, Martinez-Lopez J, Montesinos P, PETHEMA Cooperative Study Grp. Cancers. 2021 May 18;13(10):2458. doi: 10.3390/cancers13102458. PMID: 34070172

The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study. Perez Encinas M, Sobas M, Gomez-Casares M, Abuin Blanco A, Noya Pereira M, Raya J, Andrade-Campos M, Alvarez Larran A, Lewandowki K, Lukasz S, Hernandez Boluda J, Ferrer-Marin F, Fox M, Golos A, Gasior Kabat M, Magro Mazo E, Czyz A, Martin Martin A, Bellosillo Paricio B, Quinteiro Garcia C, Gonzalez Martin J, Stuckey R. European Journal of Haematology. 2021 Mar;106(3):371-379. doi: 10.1111/ejh.13561. PMID: 33275803

The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study. Martinez-Lopez J, Mustjoki S, Porkka K, Klisovic R, Wolf D, Busque L, Hernandez-Boluda J, Swanink R, Regueira P, Lipton J. Leukemia & Lymphoma. 2021 Aug;62(8):2040-2043. doi: 10.1080/10428194.2021.1889536. PMID: 33653205

Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis. McLornan D, Eikema DJ, Czerw T, Kroger N, Koster L, Reinhardt HC, Angelucci E, Robin M, Bornhauser M, Passweg J, Clark A, Vydra J, Blau IE, Niittyvuopio R, Platzbecker U, Cornelissen JJ, Chevallier P, Srour M, Stamatovic D, Martinez-Lopez J, de Wreede L, Hayden P, Hernandez-Boluda JC, Yakoub-Agha I.Bone Marrow Transplantation. 2021 Sep;56(9):2160-2172. doi: 10.1038/s41409-021-01305-x. PMID: 33911203

Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. Alvarez-Larran A, Sant’Antonio E, Harrison C, Kiladjian J, Griesshammer M, Mesa R, Ianotto J, Palandri F, Hernandez-Boluda J, Birgegard G, Nangalia J, Koschmieder S, Rumi E, Barbui T. Lancet Haematology. 2021 Sep;8(9):e658-e665. doi: 10.1016/S2352-3026(21)00204-0. PMID: 34450103

Proyectos
Referencia: PI21/00538
Título: Factores clinicobiológicos y genéticos asociados al riesgo de trombosis en la mielofibrosis
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Juan Carlos Hernández Boluda
Duración: 2022 – 2024
Presupuesto: 96.800 €
Referencia: GLD16/00047
Título: Molecular characterisation with NGS of patients with essential thrombocythaemia or polycythaemia vera who develop resistance to hydroxycarbamide according to the European LeukemiaNet criteria
Entidad Financiadora: Gilead Fellowship Program
Investigador principal: José V. Cervera Zamora
Duración: 2018 – 2019
Presupuesto: 49.657 €
+ Información
Título: Significado pronóstico de la expresión del factor de crecimiento endotelial vascular (VEGF) y de genes implicados en las vías de señalización del VEGF en pacientes con leucemia aguda mieloblástica
Doctorando: Calabuig Muñoz, Marisa
Director: Tormo Díaz, Mar; Solano Vercet, Carlos
Fecha: 04/05/2022
Universidad: Universitat de València

Título: Rol del complejo RUNX1-CBF-Β/HIPK2/p300/p53 en la evolución leucémica de las neoplasias mieloproliferativas crónicas
Doctorando: Lozano Asencio, Carlos Alberto
Director: Hernández Boluda, Juan Carlos; Climent Bataller, Joan
Fecha: 14/02/2020
Universidad: Universitat de València

Título: Caracterización molecular de la anemia refractaria con sideroblastos en anillo mediante un panel de secuenciación de segunda generación
Doctorando: Martín Castillo, Iván
Director: Sanz Alonso, Miguel Ángel; Such Taboada, Esperanza; Cervera Zamora, Jose Vicente
Fecha: 06/02/2020
Universidad: Universitat de València

Título: Análisis de la relación coste-efectividad del tratamiento con azacitidina en pacientes con síndrome mielodisplásico en el hospital clínico universitario de valencia
Doctorando: Torrecilla Junyent, Teresa
Director: Alós Almiñana, Manuel; Tormo Díaz, María del Mar; Cortijo Gimeno, Julio
Fecha: 12/06/2019
Universidad: Universitat de València